Monday, 30 November 2020

12 November 2020

Dr Louise Hill presents sub-study findings at ESPID 2020

Candida and Vancomycin Resistant Enterococcus Colonisation in Septic Neonates on Vancomycin Treatment Neonates are colonised rapidly within the first few hours of life. Antibiotic exposure can disrupt the normal pattern of colonisation, leading to colonisation with resistant bacteria and fungi, e.g. vancomycin resistant enterococci (VRE) and candida . Colonisation with VRE and candida can increase the risk of invasive infection with associated morbidity and mortality.

Overall colonisation and acquisition of colonisation with candida and VRE were evaluated. Colonisation at 3 body sites and 3 timepoints were compared between septic infants treated with either a short course (with a loading dose) or a long course (no loading dose) of vancomycin (www.neovanc.org). No difference was seen in acquisition of candida or VRE between treatment arms. VRE colonisation was infrequent (4.7%). Candida colonisation was more prevalent with overall colonisation rates being high (33.1%). Candida albicans was the most common colonising species, butnon-C. albicans species were more common in cases of acquisition, likely acquired from the NICU environment.

We continue to explore ways of optimising commonly prescribed antibiotics to better treat infants as this is often different to older children and adults, as well as to help combat the global problem of antimicrobial resistance.

Login:

Reserved Access to the our services for our Partners.

Copyright © NeoVanc | All rights reserved. Read the disclaimer.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no: 602041
Call: FP7-HEALTH-2013-INNOVATION-1
Privacy policy | Terms and conditions

E-mail: info@penta-id.org